Related Experiment Video

Updated: Jun 17, 2025

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.2K

Receptors and Signaling Pathways Controlling Beta-Cell Function and Survival as Targets for Anti-Diabetic Therapeutic

Stéphane Dalle1, Amar Abderrahmani2

  • 1Institut de Génomique Fonctionnelle, Université de Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), 34094 Montpellier, France.

Cells
|August 9, 2024
PubMed

Insights

Protecting pancreatic beta-cells is key for diabetes treatment. Understanding cell receptors and signaling pathways is crucial for developing innovative therapies to preserve beta-cell function and survival.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Pharmacology

Background:

  • Pancreatic beta-cell preservation is vital for long-term diabetes management and complication prevention.
  • Current research focuses on therapeutic strategies against inflammation and hyperglycemia to protect beta-cells.
  • Understanding beta-cell receptors and signaling is essential for developing new diabetes treatments.

Purpose of the Study:

  • To review current knowledge on membrane and intracellular receptors and signaling pathways in beta-cells.
  • To identify potential therapeutic targets for protecting beta-cells from dysfunction and apoptosis.
  • To highlight pathways for developing innovative diabetes therapies.

Main Methods:

  • Comprehensive literature review of scientific publications.
  • Analysis of receptor and signaling pathway interactions within beta-cells.
  • Synthesis of existing data on therapeutic targets for beta-cell protection.

Main Results:

  • Identified key membrane and intracellular receptors involved in beta-cell function.
  • Detailed signaling pathways crucial for beta-cell survival and dysfunction.
  • Highlighted the role of these pathways as targets for novel diabetes drugs.

Conclusions:

  • Receptor and signaling pathway modulation offers promising therapeutic avenues for diabetes.
  • Protecting beta-cells from apoptosis and dysfunction is achievable through targeted interventions.
  • Further research into these pathways can lead to innovative treatments for diabetes.
Keywords:
apoptosisdiabetesinsulin secretionpancreatic beta-cellreceptorssignaling pathwaystherapeutic strategies

More Related Videos

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

11.2K
Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets09:31

Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets

Published on: June 25, 2012

14.0K

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.2K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311